Larimar Therapeutics Inc <LRMR.OQ> expected to post a loss of 32 cents a share - Earnings Preview
Larimar Therapeutics Inc LRMR.OQ LRMR.O is expected to show no change in quarterly revenue when it reports results on March 17 (estimated) for the period ending December 31 2024
LSEG's mean analyst estimate for Larimar Therapeutics Inc is for a loss of 32 cents per share.
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 12 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Larimar Therapeutics Inc is $21.00, above its last closing price of $2.61.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -0.39 | -0.37 | -0.24 | Beat | 36 |
Jun. 30 2024 | -0.32 | -0.31 | -0.34 | Missed | -11.4 |
Mar. 31 2024 | -0.23 | -0.23 | -0.27 | Missed | -14.9 |
Dec. 31 2023 | -0.26 | -0.25 | -0.30 | Missed | -21.3 |
Sep. 30 2023 | -0.21 | -0.22 | -0.21 | Beat | 6 |
Jun. 30 2023 | -0.18 | -0.19 | -0.19 | Met | 2.6 |
Mar. 31 2023 | -0.25 | -0.25 | -0.15 | Beat | 39 |
Dec. 31 2022 | -0.22 | -0.27 | -0.21 | Beat | 22.9 |
This summary was machine generated March 14 at 11:22 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
